Objective. To report the use of an extemporane ously prepared acidic suspension of itraconazole for pediatric oncology patients.
Case Summary. Itraconazole was adminis tered to a 4-year-old AML patient with Alternaria sp sinusitis. An acidic itraconazole suspension was prepared using 0.1 N hydrochloric acid and cherry syrup. Bioassay for serum itraconazole suggested the product achieved adequate peak serum con centrations.
Discussion. Fasting and reduced gastric acid ity will decrease the absorption of itraconazole. The use of an acidic suspension provides more accurate dosing for pediatric patients, allows pro vision of itraconazole in an acidic media, and allows dosing in patients unable or unwilling to swallow capsules.
Conclusions. Itraconazole prepared in an acidic suspension appears to be absorbed. Further study is needed to establish stability of this prepa ration, as well as, the extent and consistency of its absorption.
Anonymous.Itraconazole. Product monograph. Janssen Pharmaceutica. Titusville, NJ . March 1994.
2.
Thunnissen Plm , Sizoo W., Hendriks Wdh.Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med.1991; 39:84 -91.
3.
Cutsem JV, Gerven FV, Janssen Paj.Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Rev Infect Dis.1987;9: S15-S32.
4.
Kintzel PE, Rollins CJ, Yee WJ, List AFLow itraconazole serum concentrations following administration of itraconazole suspention to critically ill allogeneic bone marrow transplant recipients . Ann Pharmacother.1995;29:140-143.
5.
Jacobson PA, Johnson CE, Walters JRStability of itraconazole in an extemporaneously compounded oral liquid. Am J Health Syst Pharm.1995;52:189- 191.
